#OP0114 at #EULAR2026: Spanish study finds marked regional disparities in premature mortality from systemic connective tissue diseases. Higher socioeconomic deprivation and longer waits for specialist care were both linked to worse outcomes. @RheumNow https://t.co/04we2H0wdb

• https://x.com/DrMiniDey/status/2062216491521523771/photo/1

ULT de-escalation in Gout: shall we do it? Short answer: No RCT 309 pts 24 mo Primary outcome remission last 6 mo 79.2% ULT continuation vs 62.9% discontinuation p=0.002 Flare incidence 12% vs 32% More NSAID/colchicine use after stopping ULT Stopping ULT = urate rises quickly & https://t.co/bYKr5axu46

• https://x.com/AurelieRheumo/status/2062216425427595640/photo/1

❎HIGH Type 1 #interferon = Worse #scleroderma In both #limited #lcSSc & #diffuse #dcSSc Leeds cohort ?biomarker #EULAR2026 @RheumNow ABST#POS1092 ABST#POS0395 https://t.co/cRrBIpLgP9

• https://x.com/Janetbirdope/status/2062216031255359658/photo/1
• https://x.com/Janetbirdope/status/2062216031255359658/photo/1

#EULAR2026 OP0126 Long-term extension study up to 108 weeks: Ianalumab demonstrated sustained efficacy (change in ESSDAI) including those who switched from PBO to IAN in #Sjogren. IAN improved most domains apart from lungs, MSK & Haem - important to note @RheumNow #EULARBest https://t.co/x1d4G1s0jw

• https://x.com/Yuz6Yusof/status/2062215758721974393/photo/1
• https://x.com/Yuz6Yusof/status/2062215758721974393/photo/1

#OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with higher stroke-related mortality and disability. Encouragingly, excess stroke risk was no longer significant in more recent RA cohorts. @RheumNow

Izokibep IL-17A Affibody PsA 343 pts RCT PBO crossover wk16 52 wks data ACR50 50–57% ACR70 36–42% PASI100 64% MDA 47–52% No diff between QW vs Q2W AE Injection-site reactions, URTIs most common No new safety signals Looks like any other IL17Ai to me #EULAR2026 #OP073 https://t.co/WiHT8Plitn

• https://x.com/AurelieRheumo/status/2062215108231663736/photo/1

Can we intercept PsA? Retro study 394 PSO pts 17 yrs follow-up 86 PsA TNFi linked to higher PsA incidence vs IL- MoA TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11% After adjustment IL-17i HR 0.35 IL-23i HR 0.17 Needs prospective confirmation! #OP072 #EULAR2026 https://t.co/88RaukjLjY

• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1
• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1
• https://x.com/AurelieRheumo/status/2062213643710714098/photo/1

#OP090 at #EULAR2026: In this nationwide Danish study, RA patients with lung cancer had similar survival outcomes to patients without RA. Importantly, immune checkpoint inhibitor treatment did not appear to worsen outcomes in patients with pre-existing RA. @RheumNow

At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics https://t.co/IaJ1gyECZu

• https://x.com/synovialjoints/status/2062211485212832125/photo/1

Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886

• https://x.com/synovialjoints/status/2062210281942417906/photo/1

#OP089 at #EULAR2026 provides real-world data on biologic use after new cancer diagnoses in RA. Continuing biologics in early-stage cancer, & restarting them in many stage 2-3 cancers, was not associated with worse 5-year survival in this Japanese registry study. @RheumNow https://t.co/OdCPiCxFEq

• https://x.com/DrMiniDey/status/2062210199776112880/photo/1

22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026

#EULAR2025 OP0127 Still trying to get my head around the flat line PBO response. In Sjogren pts with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met all endpoints. ESSPRI improved too! Could be because strict concom DMARD inc. GC protocol @RheumNow https://t.co/FEhXfNPvfG

• https://x.com/Yuz6Yusof/status/2062208779366592774/photo/1

In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV

• https://x.com/synovialjoints/status/2062208390512660905/photo/1